UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 22, 2005
Sirna Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware | | 0-27914 | | 34-1697351 | |
(State or other jurisdictionof incorporation) | | (Commission File No.) | | (I.R.S. EmployerIdentification Number) | |
2950 Wilderness Place
Boulder, Colorado 80301
(Address of principal executive offices)
Registrant’s telephone number, including area code: (303) 449-6500
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01REGULATION FD DISCLOSURE |
Sirna Therapeutics, Inc. (the “Company”) issued a press release on Tuesday, February 22, 2005 that Howard W. Robin, the Company’s President and Chief Executive Officer, is scheduled to give a Company presentation at BIO CEO & Investor Conference to be held from February 23 to 24, 2005 at The Waldorf-Astoria in New York City. The Company’s presentation will start at 3:30 p.m. EST on Thursday, February 24, 2005.
The presentation will be available via webcast beginning February 24 and can be found at the Company’s web site at www.sirna.com. The webcast will also be archived on the Company's web site for 30 days.
A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information contained in this Item 7.01, including the accompanying exhibit, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liability of that section. The information contained in this Item 7.01, including the accompanying exhibit, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing.
ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS |
(c) Exhibits.
| | 99.1 | Press Release issued by Sirna Therapeutics, Inc. on February 22, 2005. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 23, 2005
SIRNA THERAPEUTICS, INC. (Registrant) | |
By:/s/ Howard W. Robin | |
| Name:Howard W. Robin | |
| Title:President and Chief Executive Officer | |
EXHIBIT INDEX
| | 99.1 | Press Release issued by Sirna Therapeutics, Inc. on February 22, 2005. |
